gutflix
GI learning, personalised

Summary

EFFICACY AND SAFETY OF A NOVEL FULLY SYNTHETIC AND SELF-ASSEMBLING PEPTIDE SOLUTION FOR SUBMUCOSAL INJECTION IN ENDOSCOPIC MUCOSAL RESECTION OF COLORECTAL TUMORS: A MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY

Toshio Uraoka

UEG Week Vienna 2024 | Poster

Colorectal

October 13, 2024

A prospective study of 110 colorectal lesions in Japan evaluated PuraLift, a novel self-assembling peptide submucosal injection solution, for endoscopic mucosal resection and found high rates of en-bloc resection with minimal need for re-injection and no intraoperative complications.

KEY POINTS

- En-bloc resection was achieved in 99.1% (109/110) of colorectal neoplastic lesions measuring 5–20 mm using PuraLift as the submucosal injection solution
- Only two patients required additional injection due to loss of mucosal lesion lifting, with a mean injection volume of 2.01 mL
- No cases of bleeding, perforation, or other accidental intraoperative events were observed during the study period
- The procedure was rated as easy or normal in 99.1% of cases, though 7.3% of lesions showed inconclusive horizontal margins on histopathological evaluation
- This material may be of interest to endoscopists performing colorectal EMR seeking alternatives to conventional submucosal injection solutions

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/67d92a24-9111-11ef-beea-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.